Evaluating ultrasound parameters to predict bleeding risks in pregnant women with placenta previa
Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study
This study is testing if certain ultrasound measurements can help predict bleeding risks in pregnant women with placenta previa between 28 and 37 weeks of pregnancy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 68 (estimated) |
| Sex | Female |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT05802251 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to assess the effectiveness of specific ultrasonographic parameters, including cervical length, placental thickness, and the distance from the placental edge to the internal os of the cervix, in predicting the risk of antepartum hemorrhage and emergency cesarean delivery in asymptomatic women diagnosed with placenta previa. The study focuses on women between 28 and 37 weeks of gestation, as this is a critical period for managing pregnancies with placenta previa. By analyzing these sonographic findings, the research seeks to improve management strategies for high-risk patients, potentially leading to better maternal and neonatal outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are asymptomatic women diagnosed with placenta previa between 28 and 37 weeks of gestation.
Not a fit: Patients with multiple pregnancies, a history of bleeding in the current pregnancy, or other specified exclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict and manage antepartum hemorrhage risks, leading to improved safety for both mothers and infants.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have indicated the importance of ultrasound in managing placenta previa, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Asymptomatic women diagnosed with placenta previa according to RCOG (GTG No. 27a, 2018): placenta lies directly over the internal os for pregnancies more than 16 weeks' gestation on transabdominal or transvaginal scanning. * Gestational age between 28 till 37 weeks' gestation (as delivery should be considered between 36 and 37 weeks of gestation for women presenting with uncomplicated placenta previa) Exclusion Criteria: * Multiple pregnancies. * Threatened preterm labor or preterm rupture of membranes. * History of bleeding in the current pregnancy. * Polyhydraminos (AFI \> 25 cm). * History of cervical surgery (cone biopsy). * Presence of cervical cerclage. * Maternal use of vaginla progesterone. * History of maternal disease (hypertensive, DM, Cardiac). * Fetal malformation or growth restriction
Where this trial is running
Cairo
- Faculty of Medicine, Ain Shams University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Maya Abdelrazek, MD
- Email: dr_maya89@med.asu.edu.eg
- Phone: 01222393983
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.